MDX2001 — Topline data
2026
The MDX2001 CMet-Trop2/CD3-CD28 tetraspecific antibody has advanced to the fifth dose level in its Phase 1 clinical trial, with Phase 1b studies in selected solid tumors expected in 2026.Source filing
OPK biotech catalysts & pipeline
OPKO HEALTH INC · Data as of 2026-09-08
Upcoming catalysts
long-acting PTH tablet — IND submission
late 2026
Following favorable pharmacodynamic and pharmacokinetic data reported in December 2025, the companies have jointly decided to accelerate development and expect to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) in late 2026.Source filing
MDX2301 — Initial data
Sep 2026–Apr 2027
Initiated MDX2301 Phase 1 clinical trial for the prevention of COVID-19, with plans to complete enrollment in the third quarter 2026 and early data to be presented in late 2026 or early 2027.Source filing
MDX2004 — Initial data
H1 2027
We expect to report initial safety, tolerability, pharmacokinetic and immune data in the first half of 2027.Source filing